Intellia Therapeutics (NTLA) Depreciation and Depletion (2015 - 2017)
Intellia Therapeutics (NTLA) posted quarterly Depreciation and Depletion of $660000.0 for Q1 2017, up 252.94% year-over-year from $187000.0 in Q1 2016, and up 64.59% quarter-over-quarter from $401000.0 in Q4 2016.
Intellia Therapeutics (NTLA) Depreciation and Depletion (2015 - 2017) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Depreciation and Depletion for 3 consecutive years, with $660000.0 the latest figure, recorded in Q1 2017.
- In Q1 2017, Depreciation and Depletion rose 252.94% year-over-year to $660000.0; the TTM figure through Mar 2017 stood at $1.6 million (up 246.48% YoY), while the FY2017 annual figure was $3.0 million, up 172.73% from the prior year.
- Depreciation and Depletion climbed to $660000.0 in Q1 2017 per NTLA's latest filing, from $401000.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $660000.0 in Q1 2017 and bottomed at $33000.0 in Q1 2015.
- Historically, Depreciation and Depletion has averaged $228888.9 across 3 years, with a median of $187000.0 in 2016.
- On a YoY basis, Depreciation and Depletion climbed as much as 466.67% in 2016 and fell as far as 176.04% in 2016.
- Intellia Therapeutics' Depreciation and Depletion stood at $104000.0 in 2015, then surged by 285.58% to $401000.0 in 2016, then soared by 64.59% to $660000.0 in 2017.
- Business Quant data shows NTLA's Depreciation and Depletion at $660000.0 in Q1 2017, $401000.0 in Q4 2016, and $265000.0 in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 38.91 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 660,000.00 |
| Mar 31, 2017 | 660,000.00 |
| Dec 31, 2016 | 401,000.00 |
| Dec 31, 2016 | 401,000.00 |
| Sep 30, 2016 | 265,000.00 |
| Sep 30, 2016 | 265,000.00 |
| Jun 30, 2016 | 247,000.00 |
| Jun 30, 2016 | 247,000.00 |
| Mar 31, 2016 | 187,000.00 |
| Mar 31, 2016 | 187,000.00 |
| Dec 31, 2015 | 104,000.00 |
| Dec 31, 2015 | 104,000.00 |
| Sep 30, 2015 | 96,000.00 |
| Sep 30, 2015 | 96,000.00 |
| Jun 30, 2015 | 67,000.00 |
| Jun 30, 2015 | 67,000.00 |
| Mar 31, 2015 | 33,000.00 |
| Mar 31, 2015 | 33,000.00 |